Zogenix Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
80,856.00
8,587.00
26,144.00
69,707.00
125,227.00
Depreciation, Depletion & Amortization
1,806.00
1,625.00
1,621.00
1,402.00
425.00
Other Funds
29,944.00
93,257.00
13,326.00
13,188.00
37,479.00
Funds from Operations
49,106.00
83,045.00
39,041.00
56,142.00
87,323.00
Changes in Working Capital
4,186.00
2,229.00
14,159.00
16,738.00
11,449.00
Net Operating Cash Flow
44,920.00
80,816.00
64,602.00
72,880.00
75,874.00
Capital Expenditures
810.00
122.00
308.00
103.00
76.00
Sale of Fixed Assets & Businesses
-
89,624.00
82,984.00
-
-
Purchase/Sale of Investments
-
-
4,371.00
-
-
Net Investing Cash Flow
810.00
61,002.00
87,047.00
103.00
76.00
Issuance/Reduction of Debt, Net
-
12,064.00
1,450.00
1,167.00
20,000.00
Net Financing Cash Flow
76,523.00
10,002.00
92,201.00
817.00
277,902.00
Net Change in Cash
30,793.00
29,816.00
114,646.00
73,800.00
201,952.00
Free Cash Flow
45,730.00
80,938.00
64,910.00
72,983.00
75,950.00
Deferred Taxes & Investment Tax Credit
-
-
2,050.00
1,025.00
-
Net Assets from Acquisitions
-
28,500.00
-
-
-
Change in Capital Stock
76,523.00
2,062.00
93,651.00
350.00
299,767.00
Extraordinaries
-
-
89,484.00
-
-

About Zogenix

View Profile
Address
5959 Horton Street
Emeryville California 94608
United States
Employees -
Website http://www.zogenix.com
Updated 07/08/2019
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.